PAS
CPRX icon

Point72 Asia (Singapore)’s Catalyst Pharmaceutical CPRX Stock Holding History

Point72 Asia (Singapore)’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,857
Closed -$153K – 1036
2024
Q2 		$153K Buy
+9,857
New +$153K 0.03% 368
2024
Q1 		– Sell
-1,577
Closed -$26.5K – 1093
2023
Q4 		$26.5K Buy
+1,577
New +$21.6K 0.01% 411

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Point72 Asia (Singapore)'s CPRX Position: Q3 2024 in Review

Point72 Asia (Singapore) sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 9,857 shares — an estimated $153K sold.

Point72 Asia (Singapore) first reported a position in CPRX in Q4 2023 and held it in 2 quarters. The position peaked at $153K in Q2 2024. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

  • Point72 Asia (Singapore) reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 9,857 Catalyst Pharmaceutical shares in Q3 2024, an estimated $153K.
  • Point72 Asia (Singapore) first reported a position in Catalyst Pharmaceutical in Q4 2023 and held it in 2 quarters.
  • Point72 Asia (Singapore)'s Catalyst Pharmaceutical position peaked at $153K in Q2 2024.
  • 316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2024, filed 14 Nov 2024.